



SAFETY DATA SHEET

Product Name: Ceftriaxone for Injection

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

Manufacturer Name And Address	Hospira, Inc. 275 North Field Drive Lake Forest, Illinois 60045 USA
Emergency Telephone	CHEMTREC: North America: 800-424-9300; International 1-703-527-3887; Australia - 61-290372994; UK - 44-870-8200418
Hospira, Inc., Non-emergency	224 212-2000
Product Name	Ceftriaxone for Injection
Synonyms	(6 <i>R</i> ,7 <i>R</i>)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[1,2,5,6-tetrahydro-2-methyl-5,6-dioxo- <i>as</i> -triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7 <i>Z</i> -(<i>Z</i>)-(0-methyloxime), disodium salt, sesquaterhydrate.

2. HAZARD(S) IDENTIFICATION

Emergency Overview	Ceftriaxone for Injection is a powder for reconstitution containing ceftriaxone sodium, a cephalosporin antibacterial agent used clinically to treat infections due to susceptible organisms. In the workplace, the powdered ceftriaxone sodium may produce skin, eye, or respiratory irritation, and should be considered a potential sensitizer. The reconstituted product is not anticipated to be irritating. Persons known to be allergic to penicillins or other cephalosporins should take precautions when handling open containers of this material. Following an accidental over-exposure, possible target organs may include the gastrointestinal system, liver, kidneys, blood, and skin.
---------------------------	---

U.S. OSHA GHS Classification

Physical Hazards	Hazard Class	Hazard Category
	Not Classified	Not Classified
Health Hazards	Hazard Class	Hazard Category
	Eye Damage/Irritation	2B
	Sensitization – Skin	1
	Sensitization – Respiratory	1
	STOT - RE	2

Label Element(s)

Pictogram



Signal Word

Danger

Hazard Statement(s)

Causes eye irritation
 May cause an allergic skin reaction
 May cause allergic or asthmatic symptoms or breathing difficulties if inhaled
 May cause damage to organs through prolonged or repeated exposure.

2. HAZARD(S) IDENTIFICATION: continued

Precautionary Statement(s)

Prevention	<p>Do not breathe dust/vapors/spray. In case of inadequate ventilation, wear respiratory protection. Wear protective gloves. Wash hands thoroughly after handling. Contaminated work clothing must not be allowed out of the workplace.</p>
Response	<p>Get medical attention if you feel unwell.</p> <p>IF INHALED: If breathing is difficult, remove person to fresh air and keep comfortable for breathing. If experiencing respiratory symptoms: Call a doctor.</p> <p>IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention.</p> <p>IF ON SKIN: Wash with plenty of water. If skin irritation or rash occurs: Get medical advice/attention. Wash contaminated clothing before reuse.</p>

3. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient Name Ceftriaxone Sodium
Chemical Formula C₁₈H₁₆N₈Na₂O₇S₃• 3.5H₂O

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Ceftriaxone Sodium	100	74578-69-1	XI0368800

4. FIRST AID MEASURES

Eye Contact	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Skin Contact	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Inhalation	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Ingestion	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability	None anticipated for this product. However, many organic powders will combust at elevated temperatures.
Fire & Explosion Hazard	None anticipated for this product. Avoid the creation of dusty environments.
Extinguishing Media	As with any fire, use extinguishing media appropriate for primary cause of fire such as carbon dioxide, dry chemical extinguishing powder or foam.
Special Fire Fighting Procedures	No special provisions required beyond normal firefighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal If a container breaks, isolate area around spill. Put on suitable protective clothing and equipment as specified by site spill control procedures. Collect the spilled powder using techniques that minimize powder migration. Clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.

If a spill occurs after reconstitution, absorb liquid with suitable material and clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling No special handling required for hazard control under conditions of normal product use.

Storage No special storage required for hazard control. For product protection, follow storage recommendations noted on the product case label, the primary container label, or the product insert.

Special Precautions No special precautions required for hazard control. Persons with known allergies to penicillins or other cephalosporins should consult a health or safety professional prior to handling open containers of this material.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

Component	Exposure Limits			
	OSHA-PEL	ACGIH-TLV	AIHA WEEL	Hospira EEL
Ceftriaxone Sodium	8-hr TWA: Not Established			

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit
 ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.
 AIHA WEEL: Workplace Environmental Exposure Level
 EEL: Employee Exposure Limit.
 TWA: 8-hour Time Weighted Average.

Respiratory Protection Respiratory protection is normally not needed during intended product use. However, if the generation of dusts or aerosols is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N95 or equivalent) is recommended under conditions where airborne dust or aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required.

Skin Protection If skin contact with the product formulation is likely, the use of latex or nitrile gloves is recommended.

Eye Protection Eye protection is normally not required during intended product use. However, if eye contact is likely to occur, the use of chemical safety goggles (as a minimum) is recommended.

Engineering Controls Engineering controls are normally not needed during the normal use of this product.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State	Ceftriaxone sodium is a white to yellowish crystalline powder. The color of ceftriaxone solutions ranges from light yellow to amber.
Odor	Practically odorless
Odor Threshold	NA
pH	6.7 for a 1% aqueous solution
Melting point/Freezing Point	NA
Initial Boiling Point/Boiling Point Range	NA
Flash Point	NA
Evaporation Rate	NA
Flammability (solid, gas)	NA
Upper/Lower Flammability or Explosive Limits	NA
Vapor Pressure	NA
Vapor Density (Air =1)	NA
Relative Density	NA
Solubility	Readily soluble in water, sparingly soluble in methanol and very slightly soluble in ethanol.
Partition Coefficient: n-octanol/water	NA
Auto-ignition Temperature	NA
Decomposition Temperature	NA
Viscosity	NA

10. STABILITY AND REACTIVITY

Reactivity	Not determined.
Chemical Stability	Stable under standard use and storage conditions.
Hazardous Reactions	Not determined
Conditions to Avoid	Not determined
Incompatibilities	Not determined.
Hazardous Decomposition Products	Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides (CO _x), nitrogen oxides (NO _x), sodium oxides (Na _x O _x), and sulfur oxides (SO _x).
Hazardous Polymerization	Not anticipated to occur with this product.

11. TOXICOLOGICAL INFORMATION

Acute Toxicity - Not determined for the product formulation. Information for the active ingredient is as follows:

Ingredient(s)	Percent	Test Type	Route of Administration	Value	Units	Species
Ceftriaxone Sodium Hydrate	100	LD50	Oral	>10,000	mg/kg	Rat, Mouse
Ceftriaxone Sodium Hydrate	100	LD50	Intravenous	1900 2200 >3000	mg/kg mg/kg mg/kg	Rat Mouse Dog

LD50 is the dosage producing 50% mortality

11. TOXICOLOGICAL INFORMATION: continued

Occupational Exposure Potential	Minimal occupational exposure is anticipated from normal handling of the intact container. Avoid liquid aerosol generation and inadvertent skin contact.
Signs and Symptoms	None anticipated from normal handling of this product. Based on clinical use of this product in patients, following an accidental occupational exposure, possible adverse effects may include gastrointestinal upset (nausea, vomiting, stomach cramps, loss of appetite), headache, dizziness, elevated liver enzymes, elevated kidney enzyme levels, and altered hematological parameters (anemia, neutropenia, thrombocytopenia). Persons allergic to penicillins or other cephalosporin antibiotics may experience allergic reactions including fever, rash, itching, difficulty breathing, or anaphylaxis.
Aspiration Hazard	None anticipated from normal handling of this product.
Dermal Irritation/ Corrosion	None anticipated from normal handling of this product.
Ocular Irritation/ Corrosion	None anticipated from normal handling of this product. However, inadvertent contact of this product with eyes may produce irritation with redness and tearing.
Dermal or Respiratory Sensitization	None anticipated from normal handling of this product. As a class, cephalosporin antibiotics are sensitizers in studies in animals. Allergic reactions have been reported during the clinical use of this product.
Reproductive Effects	None anticipated from normal handling of this product. Ceftriaxone produced no impairment of fertility when given intravenously to rats at daily dosages up to 586 mg/kg/day, about 20 times the recommended clinical dose of 2 gm/day. Reproductive studies in mice and rats at doses up to 20 times the usual human dose have shown no evidence of embryotoxicity, fetotoxicity or teratogenicity. In primates, no embryotoxicity or teratogenicity was noted at a dose about three times the human dose. In rats, in the Segment I (fertility and general reproduction) and Segment III (perinatal and postnatal) studies using intravenous ceftriaxone at doses of 586 mg/kg/day or less, no adverse effects were noted on various reproductive parameters during gestation and lactation, including postnatal growth, functional behavior and reproductive ability of the offspring.
Mutagenicity	The mutagenic potential of ceftriaxone was evaluated in the Ames test, a micronucleus test, and an <i>in vitro</i> test for chromosomal aberrations in human lymphocytes. Ceftriaxone showed no potential for mutagenic activity in these studies.
Carcinogenicity	Carcinogenicity studies with ceftriaxone in animals have not been conducted.
Carcinogen Lists	IARC: Not listed NTP: Not listed OSHA: Not listed
Specific Target Organ Toxicity – Single Exposure	NA
Specific Target Organ Toxicity – Repeat Exposure	Based on clinical use, possible target organs include the gastrointestinal system, liver, kidneys, blood, and skin.

12. ECOLOGICAL INFORMATION

Aquatic Toxicity	Not determined for product.
Persistence/Biodegradability	Not determined for product.
Bioaccumulation	Not determined for product.
Mobility in Soil	Not determined for product.

Notes:

1. LC50: Concentration in water that produces 50% mortality in fish.
2. EC50: Concentration in water that produces 50% inhibition of growth in algae.

13. DISPOSAL CONSIDERATIONS

Waste Disposal	All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements.
Container Handling and Disposal	Dispose of container and unused contents in accordance with federal, state and local regulations.

14. TRANSPORTATION INFORMATION

ADR/ADG/ DOT STATUS	Not regulated
Proper Shipping Name	NA
Hazard Class	NA
UN Number	NA
Packing Group	NA
Reportable Quantity	NA
ICAO/IATA STATUS	Not regulated
Proper Shipping Name	NA
Hazard Class	NA
UN Number	NA
Packing Group	NA
Reportable Quantity	NA
IMDG STATUS	Not regulated
Proper Shipping Name	NA
Hazard Class	NA
UN Number	NA
Packing Group	NA
Reportable Quantity	NA

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

US TSCA Status	Exempt.
US CERCLA Status	Not listed
US SARA 302 Status	Not listed
US SARA 313 Status	Not listed
US RCRA Status	Not listed
US PROP 65 (Calif.)	Not listed

Notes: TSCA, Toxic Substance Control Act; CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act; SARA, Superfund Amendments and Reauthorization Act; RCRA, US EPA, Resource Conservation and Recovery Act; Prop 65, California Proposition 65

GHS/CLP Classification* *In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user.

Hazard Class	Hazard Category	Pictogram	Signal Word	Hazard Statement
NA	NA	NA	NA	NA

Prevention
 Do not breathe dust/vapors/spray.
 In case of inadequate ventilation, wear respiratory protection.
 Wear protective gloves.
 Wash hands thoroughly after handling.
 Contaminated work clothing must not be allowed out of the workplace.

15. REGULATORY INFORMATION: continued

<u>GHS/CLP Classification*</u>	continued
Response	Get medical attention if you feel unwell. IF INHALED: If breathing is difficult, remove person to fresh air and keep comfortable for breathing. If experiencing respiratory symptoms: Call a doctor. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention. IF ON SKIN: Wash with plenty of water. If skin irritation or rash occurs: Get medical advice/attention. Wash contaminated clothing before reuse. Collect spillage. Avoid release into the environment.
<u>EU Classification*</u>	*Medicinal products are exempt from the requirements of the EU Dangerous Preparations Directive.
Classification(s)	NA
Symbol	NA
Indication of Danger	NA
Risk Phrases	R42/43: May cause sensitization by inhalation and skin contact
Safety Phrases	S22: Do not breath dust S23: Do not breathe vapor/spray S24: Avoid contact with the skin S25: Avoid contact with eyes S37/39 Wear suitable gloves and eye/face protection S61: Avoid release into the environment.

16. OTHER INFORMATION

Notes:

ACGIH TLV	American Conference of Governmental Industrial Hygienists – Threshold Limit Value
CAS	Chemical Abstracts Service Number
CERCLA	US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT	US Department of Transportation Regulations
EEL	Employee Exposure Limit
IATA	International Air Transport Association
LD ₅₀	Dosage producing 50% mortality
NA	Not applicable/Not available
NE	Not established
NIOSH	National Institute for Occupational Safety and Health
OSHA PEL	US Occupational Safety and Health Administration – Permissible Exposure Limit
Prop 65	California Proposition 65
RCRA	US EPA, Resource Conservation and Recovery Act
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
STEL	15-minute Short Term Exposure Limit
STOT - SE	Specific Target Organ Toxicity – Single Exposure
STOT - RE	Specific Target Organ Toxicity – Repeated Exposure
TSCA	Toxic Substance Control Act
TWA	8-hour Time Weighted Average

16. OTHER INFORMATION: continued

MSDS Coordinator: Hospira GEHS
Date Prepared: October 17, 2012
Date Revised: June 02, 2014

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.